Skip to main content

Table 2 Changes in peak incremental exercise parameters after pulmonary rehabilitation with ghrelin or placebo

From: Effects of Ghrelin Treatment on Exercise Capacity in Underweight COPD Patients: a substudy of a multicenter, randomized, double-blind, placebo-controlled trial of ghrelin treatment

 

Ghrelin, n = 10

Placebo, n = 10

Treatment effect (95% CI; p value†)

 

Pre-treatment

Mean D.

Pre-treatment

Mean D.

 

V • o 2 mL / kg / min

13.3 (3.7)

1.4 (0.8)***

13.4 (3.2)

0.2 (1.3)

1.2 (0.2 to 2.3; 0.025)

V • o 2 mL / min

640.3 (212.5)

69.4 (45.9)

616.8 (138.8)

8.9 (59.7)

60.5 (10.5 to 110.5; 0.020)

Endurance time (s)

389 (157)

48 (96)

372 (131)

59 (60)*

-12 (-87 to 63; 0.749)

Dyspnea (Borg)

7.4 (1.5)

-0.5 (1.3)

7.2 (1.6)

-0.9 (1.8)

0.4 (-1.1 to 1.9; 0.572)

Leg discomfort (Borg)

5.5 (2.7)

-0.8 (1.8)

6.3 (2.5)

-0.6 (1.7)

-0.2 (-1.9 to 1.5; 0.803)

VT (L)

0.97 (0.17)

0.10 (0.08)**

1.05 (0.12)

0.07 (0.23)

0.03 (-0.13 to 0.19; 0.694)

f (breaths/min)

34 (7)

-2 (3)

28 (5)

-1 (6)

-1 (-5 to 4; 0.802)

V • E L / min

31.9 (6.0)

1.5 (2.7)

29.2 (6.4)

0.5 (2.2)

1.0 (-1.3 to 3.3; 0.389)

VD/VT

0.39 (0.06)

-0.04 (0.04)*

0.36 (0.05)

0.00 (0.04)

-0.04 (-0.08 to -0.00; 0.041)

V • E / V • o 2

52.5 (12.7)

-3.7 (3.7)*

48.0 (7.2)

0.5 (4.2)

-4.2 (-7.9 to -0.5; 0.030)

V • E / V • c o 2

51.0 (13.6)

-3.8 (3.9)*

45.3 (7.5)

0.4 (4.6)

-4.1 (-8.2 to -0.1; 0.045)

Pao2 (mmHg)

64.4 (16.0)

-0.5 (4.2)

66.1 (11.9)

-2.2 (5.4)

1.7 (-2.9 to 6.2; 0.454)

Paco2 (mmHg)

42.7 (7.0)

-0.3 (2.3)

42.4 (4.2)

0.7 (3.0)

-0.9 (-3.4 to 1.6; 0.453)

HR (beats/min)

118 (14)

2 (8)

113 (13)

7 (7)*

-6 (-13 to 2; 0.115)

V • o 2 / HR mL / beats

5.4 (1.5)

0.5 (0.5)*

5.5 (1.1)

-0.2 (0.5)

0.7 (0.3 to 1.2; 0.003)

Plasma LT (mg/dL)

32.3 (11.8)

3.3 (7.6)

35.0 (14.5)

2.5 (9.8)

0.9 (-7.4 to 9.1; 0.824)

Plasma NE (ng/mL)

2.45 (1.70)

-0.08 (1.29)

2.65 (1.80)

-0.11 (0.84)

0.03 (-0.99 to 1.06; 0.945)

  1. Data are presented as means (SD) unless otherwise indicated. D Difference from pre-treatment, f breathing frequency, HR Heart Rate, LT Plasma Lactate level, NE Plasma norepinephrine level, Paco 2 Arterial carbon dioxide tension, Pao 2 Arterial oxygen tension, Treatment effect, Mean difference (ghrelin minus placebo), V D /V T physiologic dead space/tidal volume ratio, V • E Minute ventilation, V • o 2 oxygen uptake, V T Tidal volume. * p < 0.05, ** p < 0.01, *** p < 0.001: change between pre-treatment and post-treatment (within-group difference) by paired t-test. † change between pre-treatment and post-treatment (treatment effect) by unpaired t-test.